Charles Ferree, MD
Internal Medicine · Charlotte, NCNPI 1346268323
Payments from drug & device makers
Across 268 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$526
- Amgen$474
- AbbVie$362
- Lilly USA, LLC$274
- AstraZeneca$268
- Johnson & Johnson$225
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,396100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $526 |
| Amgen | 27 | $474 |
| AbbVie | 18 | $362 |
| Lilly USA, LLC | 17 | $274 |
| AstraZeneca | 17 | $268 |
| Johnson & Johnson | 13 | $225 |
| Pfizer | 16 | $213 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $198 |
| Boehringer Ingelheim | 9 | $165 |
| GSK | 9 | $149 |
| Abbott | 6 | $134 |
| E.r. Squibb & Sons, L.L.C. | 7 | $124 |
| Amneal Pharmaceuticals LLC | 8 | $116 |
| Merck | 7 | $114 |
| Novartis | 6 | $108 |
| Sanofi-aventis U.S. LLC | 5 | $80 |
| IBSA Pharma Inc. | 5 | $75 |
| Idorsia Pharmaceuticals US Inc | 4 | $72 |
| Amarin Pharma, Inc. | 4 | $70 |
| Esperion Therapeutics, Inc. | 3 | $68 |
| Eisai Inc. | 4 | $66 |
| Kowa Pharmaceuticals America, Inc. | 4 | $54 |
| Bayer | 3 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $46 |
| Shire North American Group Inc | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 3 | $38 |
| Viiv Healthcare Company | 2 | $35 |
| Sanofi Pasteur Inc. | 2 | $27 |
| Genentech USA, Inc. | 1 | $25 |
| Arbor Pharmaceuticals, Inc. | 2 | $24 |
| Exact Sciences | 1 | $18 |
| Gilead | 1 | $17 |
| Nevro Corp. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Shield Therapeutics Inc | 1 | $16 |
| Bausch Health US, LLC | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Optinose US, Inc. | 1 | $15 |
| Medicure Pharma Inc. | 1 | $12 |
How this compares
$4,411 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 73 | $87,748 |
| JanuviaSitagliptin Phosphate | 18 | $28,639 |
| JardianceEmpagliflozin | 20 | $28,072 |
| XareltoRivaroxaban | 22 | $18,484 |
| MyrbetriqMirabegron | 13 | $15,400 |
| TrulicityDulaglutide | 11 | $12,566 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $10,132 |
| Rosuvastatin Calcium | 703 | $8,475 |
| Telmisartan | 239 | $8,077 |
| SynthroidLevothyroxine Sodium | 54 | $4,903 |
| Levothyroxine Sodium | 567 | $4,565 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,409 |
| Atorvastatin Calcium | 510 | $4,015 |
| Omeprazole | 260 | $3,952 |
| Celecoxib | 71 | $3,655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $213 | $90,60788 claims |
| MerckJanuvia | $114 | $28,63918 claims |
| Boehringer IngelheimJardiance | $165 | $28,07220 claims |
| Johnson & JohnsonXarelto | $225 | $18,48422 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $15,40013 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $149 | $14,54028 claims |
| Lilly USA, LLCTrulicity | $274 | $12,56611 claims |
| AbbVieSynthroid | $362 | $4,90354 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $116 | $4,565567 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Charlotte
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- Lyndsay MolinariCharlotte$2.4M
- Claud GriggCharlotte$1.5M
- Maher AghaCharlotte$1M
- Jonathan SchwartzCharlotte$824K
- Marc JohnsonCharlotte$823K
- Santosh GopalakrishnanCharlotte$598K
- Maithili ChitnavisCharlotte$536K
- Christopher FerreriCharlotte$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.